Benzinga | Jul 12, 2021 11:16AM EDT

QIAGEN Sees Net Sales $567.3M Vs $554.42M Est

* Preliminary Q2 2021 results: Net sales up 28% (+24% CER) to $567.3 million, above ~+20% CER outlook; adj. EPS up ~21% to $0.66-0.67 ($0.65-0.66 CER) vs. ~$0.62-0.64 CER outlook

* Very strong non-COVID product group sales: +52% CER growth in Q2 2021 to $407.6 million, representing 72% of total sales, expect at least 20% CER full-year growth

* Updated full-year 2021 outlook due to impact of faster-than-expected uptake of COVID-19 vaccines on test demand: At least 12% CER sales growth and at least $2.42 CER adj. EPS

* Commitment to value creation: Announcing new $100 million share repurchase program